Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cardiac Tissue Generated from Human Embryonic Stem Cells Displays Aspects of Both Mature and Immature Heart Muscle

By LabMedica International staff writers
Posted on 19 Feb 2014
An in vitro model system based on cardiac tissue generated from human embryonic stem cells displayed some of the physiological responses known to occur in the natural adult human heart while other responses more closely mimicked the immature or newborn human heart.

Cardiac experimental biology and translational research would benefit from an in vitro surrogate for human heart muscle. More...
To this end, investigators at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) studied the structural and functional properties and interventional responses of human engineered cardiac tissues (hECTs) compared to normal human heart tissues.

After transforming human embryonic stem cells into hECTs the investigators mixed them with collagen and cultured them on force-sensing elastomer devices that exercised the tissue and permitted measurement of its contractile force throughout the culture process.

Results published in the February 2014 issue of the FASEB Journal revealed that within seven to 10 days, the induced cardiac cells self-assembled into a three-dimensional strip of tissue that beat spontaneously in a manner similar to natural heart muscle. The cultured strips of tissue, which were able to survive for at least a month, displayed contractile activity in a rhythmic pattern of 70 beats per minute on average.

The heart tissue model responded to electrical and chemical stimulation and was able to incorporate new genetic information delivered by adenovirus gene therapy. During functional analysis, the hECTs displayed some responses known to occur in the natural adult human heart, while other responses more closely mimicked the immature or newborn human heart.

"We hope that our human engineered cardiac tissues will serve as a platform for developing reliable models of the human heart for routine laboratory use," said senior author Dr. Kevin D. Costa, associate professor of cardiology and at the Icahn School of Medicine at Mount Sinai. "This could help accelerate and revolutionize cardiology research by improving the ability to efficiently discover, design, develop, and deliver new therapies for the treatment of heart disease, and by providing more efficient screening tools to identify and prevent cardiac side effects, ultimately leading to safer and more effective treatments for patients suffering from heart disease."

Related Links:

Icahn School of Medicine at Mount Sinai



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.